TNG:EPA
Transgene SA
0,73 €
arrow_upward
+0,41%(+0,0030) 1K
30-sen, 9:44:44 (GMT+2) · EUR
search
Barcha belgilar
1K
5K
1O
6O
YBB
1Y
5Y
MAKS
| Belgi | Narxi | Oʻzgartirishlar | Dinamika (%) |
|---|
insights_autoTNG tikeri uchun statistika yaratilmoqda...
Ochish
0,73 €
Yuqori
0,73 €
Past
0,73 €
Bozor kapitali
203,91Â mln
Oʻrtacha hajm
156,99Â ming
Hajmi
6,23Â ming
52 haftalik eng yuqori
1,50 €
52 haftalik eng past
0,70 €
Aksiya boʻyicha daromad
-0,17 €
Muomaladagi aksiyalar
278,56Â mln
Xodimlar soni
145
Ochish
0,73 €
Yuqori
0,73 €
Past
0,73 €
Bozor kapitali
203,91Â mln
Oʻrtacha hajm
156,99Â ming
Hajmi
6,23Â ming
52 haftalik eng yuqori
1,50 €
52 haftalik eng past
0,70 €
Aksiya boʻyicha daromad
-0,17 €
Muomaladagi aksiyalar
278,56Â mln
Xodimlar soni
145
Profil
Transgene S.A. is a French biotechnology company founded in 1979. It is based in Illkirch-Graffenstaden, near Strasbourg, Alsace. The company develops and manufactures immunotherapies for the treatment of cancer. Based on viral vectors, these therapies stimulate the immune defenses of patients to specifically target cancer cells.
Transgene has two technological platforms based on these respective approaches: individual therapeutic vaccines, shared antigens cancer vaccines oncolytic viruses.
Transgene's portfolio consists of four products currently in clinical development. Its lead product TG4050, a neoantigen individualized therapeutic cancer vaccine is currently being developed in a randomized Phase I/II trial in the adjuvant treatment of head and neck cancer.
The company is listed on the regulated market of Euronext in Paris. Wikipedia
Transgene SA haqida